ZOSBIO CE Troponin I Detection Reagent Myocardial Injury Detection Protein

ZOSBIO CE Troponin I Detection Reagent Myocardial Injury Detection Protein

CTnI Overview

Cytokinin I (cTnI) is a special protein originated from cardiomyocytes. It has extraordinary function to control the contraction of cardiomyocytes. It is widely used in clinical detection of myocardial injury and unstable angina pectoris. For these patients, cTnI has the advantages of early onset, persistence, myocardial specificity and long diagnostic cycle. It is the first choice for the diagnosis of myocardial infarction.

CTnI Performance Index

CTnI Clinical Significance

Thrombin combined with ischemic evidence is helpful for the early diagnosis and treatment of type I myocardial infarction. Mastering the change law of exocrin is helpful to identify and diagnose exocrin. For example, for temporary myocardial injury caused by strenuous exercise, tachycardia and acute pulmonary embolism, CTN will temporarily increase and return to normal within 1-2 days. Chronic CTN elevation is caused by heart failure. These characteristics can help us distinguish myocardial infarction.

• Preferred marker of myocardial infarction (MI)
• We measured the size of the infarct and stratified the risk.
• Prognosis of patients with AMI

CTnI Advantages of clinical application

• Smaller molecular weight and longer time
• It is closely related to the degree of victimization

CTnI Reference

Ctnt<0.1 μg/L was normal, >0.2 μg/L was diagnostic off, and >0.5 μg/L was diagnosed as acute myocardial infarction. CTnI<0.2 μg/L was the normal value, and >1.5 μg/L was the closed value of ELISA diagnosis.

Application Department

Cardiology, first aid, examination room, pediatrics, hematology, oncology, Nephrology, surgery, etc

cTnI Clinical comparison

Company profile

Zhongxiu Science And Technology Co.,Ltd., is a high-tech enterprise engaged in the research and development, production and operation of in vitro diagnostic products. The in vitro diagnostic products developed by the company cover POCT series, microbial series, biochemical series and immune series reagents and supporting instruments.
The company has always adhered to the core concept of "fast and accurate, living up to life", committed to providing society with excellent products and services, and contributing to the cause of human health.

Zhongxiu Science And Technology Co.,Ltd., founded in 2016, is located in Dingluan Industrial Zone, Changyuan City, Henan Province. The company covers an area of about 100 acres and the initial investment is about 200 million yuan. The company has a scientific and complete management system, a purification workshop of national standards, and a fully functional inspection center. On this basis, the company will continue to invest in research and development, accumulate technical strength, update manufacturing equipment, improve production technology, improve inspection technology, improve product quality, and provide customers with safe and effective in vitro diagnostic products.

Zhongxiu Science And Technology Co., Ltd. is a high-tech enterprise engaged in the research and development, production and operation of in vitro diagnostic products. The in vitro diagnostic products developed by the company cover POCT series, immune series, microbial series and other reagents and supporting instruments.

The company has always adhered to the core concept of “fast and accurate, living up to life”, committed to providing society with excellent products and services, and contributing to the cause of human health.